Total Payments
$67,088
2024 Payments
$7,559
Companies
26
Transactions
106
Medicare Patients
7,416
Medicare Billing
$5.4M
Payment Breakdown by Category
Research$54,043 (80.6%)
Consulting$10,982 (16.4%)
Food & Beverage$1,910 (2.8%)
Education$153.91 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $54,043 | 52 | 80.6% |
| Consulting Fee | $10,982 | 10 | 16.4% |
| Food and Beverage | $1,910 | 41 | 2.8% |
| Education | $153.91 | 3 | 0.2% |
Payments by Type
Research
$54,043
52 transactions
General
$13,046
54 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $24,800 | 48 | $0 (2022) |
| Celgene Corporation | $22,543 | 1 | $0 (2017) |
| Eli Lilly and Company | $7,789 | 3 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,177 | 5 | $0 (2024) |
| Fresenius Kabi USA, LLC | $2,200 | 1 | $0 (2023) |
| Daiichi Sankyo Inc. | $2,080 | 2 | $0 (2024) |
| Amgen Inc. | $1,932 | 6 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $813.97 | 3 | $0 (2022) |
| Janssen Biotech, Inc. | $519.91 | 5 | $0 (2024) |
| ABBVIE INC. | $253.49 | 6 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,559 | 20 | AstraZeneca Pharmaceuticals LP ($3,053) |
| 2023 | $4,255 | 9 | Fresenius Kabi USA, LLC ($2,200) |
| 2022 | $25,156 | 52 | Janssen Scientific Affairs, LLC ($24,800) |
| 2021 | $128.22 | 3 | Myovant Sciences Inc. ($94.57) |
| 2020 | $38.27 | 2 | Lilly USA, LLC ($24.52) |
| 2019 | $2,052 | 4 | Eli Lilly and Company ($1,913) |
| 2018 | $5,270 | 11 | Eli Lilly and Company ($4,001) |
| 2017 | $22,630 | 5 | Celgene Corporation ($22,543) |
All Payment Transactions
106 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $15.29 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $10.72 | General |
| Category: Oncology | ||||||
| 11/07/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $21.67 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $24.30 | General |
| 10/18/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $32.00 | General |
| Category: ONCOLOGY | ||||||
| 08/29/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $130.63 | General |
| 08/19/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $555.00 | General |
| 08/19/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $33.33 | General |
| Category: ONCOLOGY | ||||||
| 07/29/2024 | Eli Lilly and Company | VERZENIO (Drug) | Consulting Fee | Cash or cash equivalent | $1,875.00 | General |
| Category: Oncology | ||||||
| 07/25/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $33.87 | General |
| Category: ONCOLOGY | ||||||
| 07/19/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Food and Beverage | In-kind items and services | $21.00 | General |
| Category: BioOncology | ||||||
| 05/28/2024 | Janssen Biotech, Inc. | RYBREVANT (Drug) | Food and Beverage | In-kind items and services | $70.17 | General |
| Category: Oncology | ||||||
| 05/15/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 04/23/2024 | ABBVIE INC. | IMBRUVICA (Drug), EPKINLY | Food and Beverage | In-kind items and services | $34.21 | General |
| Category: ONCOLOGY | ||||||
| 04/21/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $15.04 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | ABBVIE INC. | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $98.41 | General |
| Category: ONCOLOGY | ||||||
| 03/21/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,387.50 | General |
| Category: Oncology | ||||||
| 01/31/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $11.07 | General |
| Category: ONCOLOGY | ||||||
| 01/10/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $970.00 | General |
| 01/09/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| Category: Oncology | ||||||
| 08/10/2023 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $8.06 | General |
| Category: Oncology | ||||||
| 08/04/2023 | Amgen Inc. | LUMAKRAS (Drug) | Consulting Fee | Cash or cash equivalent | $649.00 | General |
| Category: Oncology | ||||||
| 08/02/2023 | Pharmacyclics LLC, An AbbVie Company | EPKINLY (Drug) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: ONCOLOGY | ||||||
| 06/20/2023 | Fresenius Kabi USA, LLC | Stimufend (Biological) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: Biosimilars | ||||||
| 06/03/2023 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $107.89 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MYLUNG | Janssen Scientific Affairs, LLC | $24,800 | 48 |
| ABI-007-MBC-001 | Celgene Corporation | $22,543 | 1 |
| A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER | Eli Lilly and Company | $5,914 | 2 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $785.42 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 44 | 1,552 | 48,041 | $5.7M | $1.4M |
| 2022 | 41 | 1,972 | 111,124 | $7.5M | $1.8M |
| 2021 | 46 | 2,031 | 61,791 | $4.8M | $1.1M |
| 2020 | 42 | 1,861 | 62,878 | $5.1M | $1.2M |
Total Patients
7,416
Total Services
283,834
Medicare Billing
$5.4M
Procedure Codes
173
All Medicare Procedures & Services
173 procedure records from CMS Medicare Utilization — Page 1 of 7
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 14 | 16,204 | $2.4M | $701,147 | 29.5% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 11 | 13,660 | $1.1M | $323,359 | 29.0% |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 2023 | 13 | 2,360 | $594,520 | $79,357 | 13.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 15 | 3,540 | $248,760 | $65,300 | 26.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 77 | 476 | $325,164 | $44,387 | 13.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 115 | 449 | $136,945 | $40,652 | 29.7% |
| J1437 | Injection, ferric derisomaltose, 10 mg | Office | 2023 | 11 | 1,300 | $100,900 | $21,045 | 20.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 199 | 322 | $66,010 | $19,101 | 28.9% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 14 | 54 | $53,244 | $6,943 | 13.0% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 23 | 147 | $48,764 | $6,888 | 14.1% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 54 | 284 | $43,168 | $5,925 | 13.7% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 114 | 504 | $31,248 | $5,216 | 16.7% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 145 | 645 | $22,575 | $4,908 | 21.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 49 | 52 | $15,600 | $4,723 | 30.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 56 | 103 | $31,312 | $4,530 | 14.5% |
| J0640 | Injection, leucovorin calcium, per 50 mg | Office | 2023 | 13 | 1,006 | $27,162 | $3,216 | 11.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 27 | 27 | $12,825 | $3,167 | 24.7% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 43 | 262 | $27,510 | $2,960 | 10.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 19 | 21 | $8,610 | $2,856 | 33.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 22 | $12,870 | $2,804 | 21.8% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 14 | 55 | $15,455 | $2,199 | 14.2% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 15 | 79 | $11,139 | $1,825 | 16.4% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 24 | 232 | $107,184 | $1,540 | 1.4% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 12 | 23 | $5,773 | $1,422 | 24.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 39 | 139 | $12,927 | $1,390 | 10.8% |
About Dr. Patrick Ward, MD
Dr. Patrick Ward, MD is a Hematology & Oncology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/02/2005. The National Provider Identifier (NPI) number assigned to this provider is 1093709297.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Patrick Ward, MD has received a total of $67,088 in payments from pharmaceutical and medical device companies, with $7,559 received in 2024. These payments were reported across 106 transactions from 26 companies. The most common payment nature is "" ($54,043).
As a Medicare-enrolled provider, Ward has provided services to 7,416 Medicare beneficiaries, totaling 283,834 services with total Medicare billing of $5.4M. Data is available for 4 years (2020–2023), covering 173 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Cincinnati, OH
- Active Since 09/02/2005
- Last Updated 04/22/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1093709297
Products in Payments
- Abraxane (Drug) $22,543
- IMFINZI (Biological) $2,498
- Stimufend (Biological) $2,200
- VERZENIO (Drug) $1,886
- KISQALI (Drug) $813.97
- LUMAKRAS (Drug) $657.06
- RYBREVANT (Drug) $290.29
- ERLEADA (Drug) $229.62
- TECENTRIQ (Biological) $165.13
- IMBRUVICA (Drug) $155.08
- KEYTRUDA (Biological) $135.67
- IMFINZI (Drug) $124.22
- TEPMETKO (Drug) $121.84
- EPKINLY (Drug) $112.69
- Rubraca (Drug) $111.92
- ORGOVYX (Drug) $94.57
- NINLARO (Drug) $45.50
- Rituxan (Biological) $42.00
- COSELA (Drug) $29.09
- IBRANCE (Drug) $26.36
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Cincinnati
Dr. David Waterhouse, Md, MD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Dr. Elyse Lower, Md, MD
Hematology & Oncology — Payments: $386,700
Hematology & Oncology $386,700
Dr. Alexander Starodub, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $254,325
Hematology & Oncology $254,325
Dr. James Essell, Md, MD
Hematology & Oncology — Payments: $223,019
Hematology & Oncology $223,019
Davendra Sohal, Md, Mph, MD, MPH
Hematology & Oncology — Payments: $124,378
Hematology & Oncology $124,378
Dr. Edward Faber, D.o., M.s, D.O., M.S
Hematology & Oncology — Payments: $116,895
Hematology & Oncology $116,895